What We're Reading: J&J Ends HCV Development; Suicides in Drug Trials; Off-Label Prescribing
HCV Field Is Getting Crowded
Johnson & Johnson’s Janssen Sciences unit will end development on a hepatitis C virus (HCV) drug.
Inaccurate Reporting of Suicides in Drug Trials
A lawsuit against GlaxoSmithKline alleges that suicide data in antidepressant clinical trials were incorrectly reported. A new report in
Asking Questions Around Off-Label Prescribing
Off-label prescribing isn’t uncommon, and can be used to help patients who haven’t responded to the FDA-approved drugs or who have a condition for which there is no drug approved yet. There are drawbacks to off-label prescribing, and
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025